When you have rheumatoid arthritis (RA) and take a biologic, the best source of daily-life advice, coping tips, and comfort may be people who are in the same boat. People with RA say they like to ...

Patients with rheumatoid arthritis who take biologic or targeted synthetic disease-modifying anti-rheumatic drugs have a 17% lower incidence of dementia than patients who take conventional, synthetic ...

Biologic drugs can be joint savers for rheumatoid arthritis (RA). But even these powerful medications don't always guarantee relief from pain and stiffness. Sometimes the first biologic you try ...

Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...

Review of recent advances in biomimetic drug delivery for rheumatoid arthritis, highlighting targeted nanomedicine strategies ...

The American College of Rheumatology has previewed its 2020 Guideline for the Management of Rheumatoid Arthritis, with new recommendations that encourage a step back from steroid use and a move toward ...

LONDON--(BUSINESS WIRE)--The global rheumatoid arthritis (RA) drugs market 2018-2022 is expected to post a CAGR of close to 8% during the forecast period, according to the latest market research ...

Please provide your email address to receive an email when new articles are posted on . “Previous studies have identified important racial and ethnic disparities in rheumatoid arthritis outcomes,” ...

These cases are further expected to increase by 2034. Biologic DMARDs and JAK Inhibitors Fuel Future Market Expansion Current therapies such as biological DMARDs showed promising results in treating ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual ...